WHAT YOU NEED TO KNOW ABOUT THE "BREAKTHROUGH" CORONAVIRUS THERAPY HERALDED BY PRESIDENT TRUMP
WHAT YOU NEED TO KNOW ABOUT THE "BREAKTHROUGH" CORONAVIRUS THERAPY HERALDED BY PRESIDENT TRUMP
"BREAKTHROUGH" "Breakthrough" "based "is "it's "major "may "remain "revised "unlikely $34.6 (EUA) (FDA) (NASDAQ: (NYSE: -- 1/2 A ABOUT ADMA ADMA) About Administration BY Bio BioSolutions Biologics CORONAVIRUS COVID-19 COVID-19. COVID-19." COVID-19? Centers Clinic Convalescent Coronavirus Defense. Department Donald Drug EBS) EUA EUA. Emergent FDA FDA's Food Fool HERALDED Health Heralded Here House However, If ImmunoTek In Is Israel-based It It's KMDA), KNOW Kamada Kayleigh Know Mayo McEnany Monday, Motley Mount NEED Need On Only PRESIDENT Patients Physicians Plasma President Provided Results Saturday Sinai Sunday System THE THERAPY TO TRUMP The Therapy There These This Trump Trump© U.S. What White WhiteHouse.gov. Who Why YOU You a about according actually after against agency agency. al. also although an and another antibodies antibodies. any approval are as at authorization available available," average based be been before behind being benefit. benefits biggest biotech blood. breakthrough breakthrough" by can care causes chloroquine clear clear, clinical collection comes comments companies company concluding conducted conference conference, conference. contains controlled convalescent coronavirus could current currently days death decision derived designs determining develop diagnosed diagnosed. didn't disease. diseases does drugs during earlier early effective effort emergency encouraging enough enzymes, et evaluating evening evidence evidence." far fight five float for found four from front-line funding future. globulin granted group. groups had half happened harvest has have healthcare help heralded his hold hours how human hydroxychloroquine hyperimmune idea immune important importantly in include including incredible infected infection inject intended into is isn't isolate issued it its jump key knock know know. known large liquid long lower main makes man medical million more most need needed new news news. next not note novel obviously of on one ongoing or other outweigh over own partnered patient's patients phase placebo plasma plasma-derived plasma. plasma? podium positive possible post-exposure potential potentially powerful president. press previously produces product product." prophylaxis proves randomized rate rates, received recommends recovered related replace represent result results. revoked revoked" risks safe said salts, same scientific secretary several sick significant six soared some specializes standard standing stated statistically still stock stocks, studies study study, success." suit system test testing than that the their therapeutic therapies therapy therapy" therapy. there these thing things this though, three thus tie: time to too transfusions treating treatment trials. tweeted two twoWHAT unaltered, until up use used viral virus. was water, were when who will winner, winners wins? with within workers. would year yellowish yet you your ©
standing next to a man in a suit and tie: What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump© Provided by The Motley Fool What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump
In his comments during the Sunday news conference, President Trump stated that convalescent plasma "is a powerful therapy" and said that "it's had an incredible rate of success." Here are the key things you need to know about this coronavirus therapy heralded by the president.
Donald Trump et al. standing next to a man in a suit and tie: President Trump behind a podium at a news conference. © WhiteHouse.gov. President Trump behind a podium at a news conference.
What is convalescent plasma?
Plasma is a clear, yellowish liquid that makes up over half of your blood. It contains water, salts, enzymes, and -- most importantly for medical treatment -- antibodies. Convalescent plasma comes from patients who have recovered from a disease.
Patients who are infected by the novel coronavirus that causes COVID-19 develop antibodies to fight the viral disease. These antibodies float in the plasma in their blood. Physicians can harvest this plasma and isolate its antibodies to inject into other sick patients who have COVID-19. The idea is that the antibodies from the convalescent plasma can help fight the novel coronavirus infection until the patient's immune system produces enough of its own antibodies to fight the virus.
Why the FDA issued EUA
The FDA stated that it granted EUA to convalescent plasma after concluding that it "may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product." This decision was "based on scientific evidence available," according to the agency.
It's important to note that EUA isn't the same thing as FDA approval of a therapy. The FDA stated that the EUA for convalescent plasma in treating COVID-19 could be "revised or revoked" in the future. This happened earlier this year when the agency revoked a previously issued EUA for chloroquine and hydroxychloroquine after determining that the drugs were "unlikely to be effective in treating COVID-19."
Is convalescent plasma a breakthrough in treating COVID-19?
It's too early to know. Convalescent plasma has been used for a long time in treating other diseases with positive results. There have also been some encouraging studies thus far of convalescent plasma in treating COVID-19.
A large clinical study conducted by the Mayo Clinic found that patients who received transfusions with convalescent plasma within three days of being diagnosed with COVID-19 had a statistically significant lower average death rate than patients who received plasma four or more days after being diagnosed. The main knock against this study, though, is that it didn't include a placebo group.
Results from randomized and controlled clinical studies with placebo groups are needed before it is clear how safe and effective convalescent plasma therapies are in treating COVID-19. The FDA stated that its EUA isn't intended to replace an